vs
Marker Therapeutics, Inc.（MRKR）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Marker Therapeutics, Inc.的季度营收约是Arcadia Biosciences, Inc.的1.2倍（$1.1M vs $901.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -154.4%，领先6.1%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -51.0%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -5.8%）
Marker Therapeutics是一家临床阶段生物技术企业，专注于开发用于癌症治疗的创新T细胞免疫疗法，产品管线覆盖血液恶性肿瘤及多种实体瘤，主要面向美国肿瘤治疗市场，致力于满足患者的未竟医疗需求。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
MRKR vs RKDA — 直观对比
营收规模更大
MRKR
是对方的1.2倍
$901.0K
营收增速更快
RKDA
高出25.2%
-51.0%
净利率更高
RKDA
高出6.1%
-154.4%
两年增速更快
RKDA
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $901.0K |
| 净利润 | $-1.7M | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -170.7% | -152.8% |
| 净利率 | -154.4% | -148.3% |
| 营收同比 | -51.0% | -25.8% |
| 净利润同比 | 55.6% | 67.1% |
| 每股收益（稀释后） | $0.02 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRKRRKDA
| Q4 25 | $1.1M | $901.0K | ||
| Q3 25 | $1.2M | $1.3M | ||
| Q2 25 | $861.2K | $1.5M | ||
| Q1 25 | $349.1K | $1.2M | ||
| Q4 24 | $2.3M | $1.2M | ||
| Q3 24 | $1.9M | $1.5M | ||
| Q2 24 | $1.2M | $1.3M | ||
| Q1 24 | $1.2M | $987.0K |
净利润MRKRRKDA
| Q4 25 | $-1.7M | $-1.3M | ||
| Q3 25 | $-2.0M | $856.0K | ||
| Q2 25 | $-4.0M | $-4.5M | ||
| Q1 25 | $-4.4M | $2.6M | ||
| Q4 24 | $-3.8M | $-4.1M | ||
| Q3 24 | $-2.3M | $-1.6M | ||
| Q2 24 | $-2.2M | $1.1M | ||
| Q1 24 | $-2.4M | $-2.4M |
毛利率MRKRRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率MRKRRKDA
| Q4 25 | -170.7% | -152.8% | ||
| Q3 25 | -173.3% | -88.5% | ||
| Q2 25 | -494.8% | -34.4% | ||
| Q1 25 | -1320.1% | 44.2% | ||
| Q4 24 | -171.5% | -187.7% | ||
| Q3 24 | -124.6% | -114.5% | ||
| Q2 24 | -197.4% | — | ||
| Q1 24 | -204.9% | -160.9% |
净利率MRKRRKDA
| Q4 25 | -154.4% | -148.3% | ||
| Q3 25 | -162.1% | 65.7% | ||
| Q2 25 | -466.3% | -306.4% | ||
| Q1 25 | -1273.6% | 216.6% | ||
| Q4 24 | -170.4% | -334.5% | ||
| Q3 24 | -119.8% | -104.9% | ||
| Q2 24 | -187.5% | 81.2% | ||
| Q1 24 | -192.3% | -245.5% |
每股收益（稀释后）MRKRRKDA
| Q4 25 | $0.02 | $-0.97 | ||
| Q3 25 | $-0.12 | $0.62 | ||
| Q2 25 | $-0.29 | $-3.26 | ||
| Q1 25 | $-0.40 | $1.90 | ||
| Q4 24 | $-0.41 | $-2.99 | ||
| Q3 24 | $-0.26 | $-1.18 | ||
| Q2 24 | $-0.25 | $0.78 | ||
| Q1 24 | $-0.27 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.1M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $16.8M | $4.1M |
| 总资产 | $19.1M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRKRRKDA
| Q4 25 | $16.1M | $4.6M | ||
| Q3 25 | $17.6M | $5.9M | ||
| Q2 25 | $10.5M | $4.4M | ||
| Q1 25 | $13.7M | $3.2M | ||
| Q4 24 | $19.2M | $4.2M | ||
| Q3 24 | $9.0M | $6.6M | ||
| Q2 24 | $7.8M | $8.1M | ||
| Q1 24 | $11.3M | $8.5M |
股东权益MRKRRKDA
| Q4 25 | $16.8M | $4.1M | ||
| Q3 25 | $18.4M | $5.4M | ||
| Q2 25 | $10.5M | $4.5M | ||
| Q1 25 | $14.5M | $8.9M | ||
| Q4 24 | $18.6M | $6.2M | ||
| Q3 24 | $7.4M | $10.3M | ||
| Q2 24 | $9.7M | $11.7M | ||
| Q1 24 | $11.8M | $10.6M |
总资产MRKRRKDA
| Q4 25 | $19.1M | $6.5M | ||
| Q3 25 | $21.7M | $8.6M | ||
| Q2 25 | $14.8M | $7.8M | ||
| Q1 25 | $17.0M | $13.0M | ||
| Q4 24 | $22.0M | $13.5M | ||
| Q3 24 | $10.9M | $15.2M | ||
| Q2 24 | $11.7M | $17.4M | ||
| Q1 24 | $14.1M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.9M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MRKRRKDA
| Q4 25 | $-1.9M | $-861.0K | ||
| Q3 25 | $-2.7M | $-257.0K | ||
| Q2 25 | $-1.9M | $-2.0M | ||
| Q1 25 | $-5.5M | $-1.6M | ||
| Q4 24 | $-4.7M | $-2.2M | ||
| Q3 24 | $1.2M | $-1.8M | ||
| Q2 24 | $-3.6M | $-2.5M | ||
| Q1 24 | $-3.8M | $-3.2M |
自由现金流MRKRRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率MRKRRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度MRKRRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率MRKRRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
